We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
- Authors
Connolly, Caoilfhionn M.; Boyarsky, Brian J.; Ruddy, Jake A.; Werbel, William A.; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline M.; Segev, Dorry L.; Paik, Julie J.
- Abstract
Rituximab has been associated with worse outcomes in patients with RMDs and SARS-CoV-2 infection ([5]), and thus it is of further concern that these patients may not derive protection from vaccination. I Background: i Patients with rheumatic and musculoskeletal diseases (RMDs) are at increased risk for SARS-CoV-2 infection because of both the immunomodulatory effects of their underlying diseases and treatment with immunosuppressive agents. Thus, we sought to analyze a subset of 20 patients with RMDs who did not develop a detectable antibody response 1 month after completion of 2-dose mRNA vaccination against SARS-CoV-2.
- Subjects
HUMORAL immunity; SARS-CoV-2; MESSENGER RNA; RHEUMATISM; MUSCULOSKELETAL system diseases
- Publication
Annals of Internal Medicine, 2021, Vol 174, Issue 9, p1332
- ISSN
0003-4819
- Publication type
letter
- DOI
10.7326/M21-1451